Electrolytes - Sodium and Potassium
Activity
Active Large Group Session
Active Large Group Session
Nephron structure and tubular functions. Diuretics and their sites and actions. Bartter and Gitelman syndromes. Hypo and hypernatremia. Hypo and hyperkalemia
Curriculum Block
Medical Foundation 2 / Part 2 / Renal / Week 3
- Indicates most relevant
Objectives
General Objectives
- Explain the structure, function and physiology of the urinary tract, kidney, nephron and glomerulus
- Choose and then analyze laboratory tests which would permit you to investigate systematically each of your hypotheses.
- Explain the mechanisms of action of diuretics, ACE inhibitors, and angiotensin receptor blocking (ARB) agents and apply them to appropriate clinical scenarios.
- Describe the determinants of intracellular fluid (ICF) and extracellular fluid (ECF) volume.
- Describe the normal distribution of sodium, potassium and water in the ICF and ECF compartments.
- Define osmolality.
- Demonstrate the role of the sodium ion in determining the osmolality of the ECF and its clinical manifestations.
- Describe and apply how the total amount of sodium in the body determines the volume of the intravascular space.
- Understand how the kidney conserves sodium appropriately during hypovolemic states, and inappropriately in the setting of congestive heart failure.
- Illustrate the mechanisms by which the kidney may excrete a dilute versus concentrated urine.
- Describe the relationship between total body water and the serum sodium concentration.
- Describe the main sites of potassium reabsorption in the nephron.
- Describe how potassium secretion by the kidney regulates the serum potassium concentration.
- Describe the role of the following in the secretion of potassium by the kidney: aldosterone activity and tubular flow rate
Assessments
Concept Application Exercise (CAE)
Tags
AFMC National Clinical Skills
Urinalysis: dipstick
Basic Sciences
Metabolism
Physiology
Curriculum Block
Medical Foundation 2
Part 2
Renal
Week 3
Curriculum Week
Part 2
Week 3
MCC Presentations
Hyperkalemia
Hypernatremia
Hypokalemia
Hyponatremia
Proteinuria
MeSH
Hydrochlorothiazide [D02.886.655.500.261.476]
Aldosterone [D04.808.745.745.654.062]
Chlorothiazide [D02.886.590.700.135.261]
Chlorothiazide [D02.886.655.500.261]
Chlorothiazide [D03.438.174.261]
Diuretics [D27.505.696.560.500]
Electrolytes [D01.248]
Fanconi Syndrome [C12.777.419.250]
Gitelman Syndrome [C12.777.419.815.491]
Hydrochlorothiazide [D02.886.590.700.135.261.476]
Hydrochlorothiazide [D03.438.174.261.476]
Hyperkalemia [C18.452.950.396]
Hypernatremia [C18.452.950.452]
Hypokalemia [C18.452.950.565]
Hyponatremia [C18.452.950.620]
Kidney Diseases [C12.777.419]
Kidney Diseases [C13.351.968.419]
Kidney Glomerulus [A05.810.453.324.359]
Kidney Glomerulus [A05.810.453.736.520]
Kidney Tubules [A05.810.453.736.560]
Kidney [A05.810.453]
Nephrons [A05.810.453.736]
Physiological Effects of Drugs [D27.505.696]
Plasma [A12.207.152.693]
Potassium [D01.268.549.550]
Proteinuria [C13.351.968.934.734]
Renal Tubular Transport, Inborn Errors [C13.351.968.419.815]
Renin-Angiotensin System [G03.820]
Saline Solution [D26.776.498.500.750]
Sodium [D01.268.549.750]
Water-Electrolyte Balance [G02.111.917]
Water-Electrolyte Imbalance [C18.452.950]